Neurogene - Multiplikator Forward P/S NGNE

The integration of AI into molecular modeling is accelerating drug development at Neurogene Inc. (NGNE). The forward P/S ratio clearly demonstrates the dynamics of market expectations, where the value 325.50 reflects the current figure. Fundamentals rely on the non-cyclical nature of gene therapy and dependence on the FDA, while future pricing power potential is limited by strict government healthcare controls.

The forward P/S multiple assesses the market value of Neurogene Inc. relative to projected revenue, allowing short-term market noise to be decoupled from the long-term fundamental trend. For Neurogene Inc. (NGNE), the forward P/S multiple trend reflects a market revaluation of gene therapy potential, where high patent values and regulatory barriers determine the asset's long-term investment attractiveness.